CERO: AI 评分 43/100 — AI 分析 (4月 2026)

CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment. Their lead candidate, CER-1236, targets hematologic malignancies and solid tumors.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

CERo Therapeutics Holdings, Inc. is a biotechnology company specializing in engineered T-cell therapies for cancer, with a focus on its lead candidate CER-1236. Operating in the competitive immunotherapy landscape, the company aims to address hematologic malignancies and solid tumors, marking its presence in the healthcare sector.

CERO是做什么的？

CERo Therapeutics Holdings, Inc., established in 2021 and headquartered in South San Francisco, California, is an immunotherapy company dedicated to pioneering the development of engineered T cell therapeutics for cancer treatment. The company's primary focus is on advancing its lead development candidate, CER-1236, an autologous T cell therapy designed to combat both hematologic malignancies and solid tumors. CERo Therapeutics is positioned within the rapidly evolving biotechnology sector, specifically targeting the immunotherapy space. Their approach involves engineering T cells to enhance their ability to recognize and destroy cancer cells, offering a potential breakthrough in cancer treatment methodologies. The company operates with a lean team of 8 employees, emphasizing a focused and agile approach to research and development. As a relatively new entrant in the biotechnology landscape, CERo Therapeutics is concentrating its efforts on preclinical and early-stage clinical development, aiming to demonstrate the safety and efficacy of CER-1236 in various cancer indications. The company's strategic location in the San Francisco Bay Area, a hub for biotechnology innovation, provides access to talent, resources, and collaborative opportunities crucial for its growth and development.

CERO的投资论点是什么？

CERo Therapeutics Holdings, Inc. presents a high-risk, high-reward investment opportunity in the competitive field of immunotherapy. The company's value hinges on the successful development and commercialization of CER-1236, its lead autologous T cell therapy candidate. Key value drivers include positive clinical trial outcomes demonstrating efficacy and safety in treating hematologic malignancies and solid tumors. The company's small size and limited operating history increase the risk profile. The potential for significant returns exists if CER-1236 achieves regulatory approval and gains market traction, but investors should carefully consider the inherent uncertainties and long development timelines associated with biotechnology investments. The company's negative profit margin of -1215.6% and gross margin of -19.6% highlight its current reliance on external funding and the need for substantial capital to advance its clinical programs.

CERO在哪个行业运营？

CERo Therapeutics Holdings, Inc. operates within the dynamic and competitive biotechnology industry, specifically focusing on immunotherapy. The global immunotherapy market is experiencing substantial growth, driven by advancements in T cell engineering and the increasing prevalence of cancer. Major players and smaller innovative companies are vying for market share. CERo Therapeutics aims to differentiate itself through its CER-1236 therapy. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy in a crowded field. The industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles.

Biotechnology

Healthcare

CERO有哪些增长机遇？

Advancement of CER-1236 Clinical Trials: CERo Therapeutics' primary growth opportunity lies in successfully advancing CER-1236 through clinical trials. Positive results in Phase 1 and Phase 2 trials would validate the therapy's potential and attract further investment and partnerships. The market for T cell therapies is projected to reach billions of dollars by 2030, offering substantial revenue potential if CER-1236 proves effective. The timeline for realizing this opportunity depends on the pace of clinical development and regulatory approvals.
Expansion of Target Indications: CERo Therapeutics can expand its growth potential by exploring additional cancer indications for CER-1236 beyond hematologic malignancies and solid tumors. This could involve preclinical research to assess the therapy's efficacy against other cancer types. Expanding the target market would significantly increase the commercial opportunity for CER-1236. This expansion could begin within the next 2-3 years, contingent on initial clinical trial results.
Strategic Partnerships and Collaborations: CERo Therapeutics can accelerate its growth by forming strategic partnerships with larger pharmaceutical companies or research institutions. These collaborations could provide access to funding, expertise, and resources necessary to advance CER-1236 through clinical development and commercialization. Partnerships could also facilitate the expansion of the company's research and development pipeline. These partnerships could materialize within the next 1-2 years.
Development of Next-Generation T Cell Therapies: CERo Therapeutics can invest in research and development to create next-generation T cell therapies with improved efficacy and safety profiles. This could involve exploring novel T cell engineering techniques or targeting new cancer antigens. Developing a pipeline of innovative therapies would enhance the company's long-term growth prospects and competitive advantage. Investment in next-generation therapies could begin within the next year.
Securing Orphan Drug Designation: CERo Therapeutics should pursue orphan drug designation for CER-1236 in specific cancer subtypes with limited treatment options. Orphan drug designation provides regulatory and financial incentives, including market exclusivity and tax credits, which can accelerate the development and commercialization of the therapy. This designation would enhance the attractiveness of CER-1236 to potential partners and investors. The company can apply for orphan drug designation within the next year.

CERo Therapeutics Holdings, Inc. was incorporated in 2021, making it a relatively new player in the biotechnology industry.
The company's primary focus is on developing CER-1236, an autologous T cell therapy candidate for treating hematologic malignancies and solid tumors.
CERo Therapeutics operates with a small team of 8 employees, indicating a lean operational structure.
The company's profit margin is -1215.6%, reflecting its current stage of development and reliance on research and development spending.
The company's shares trade on the OTC market, indicating a higher risk profile compared to companies listed on major exchanges.

CERO提供哪些产品和服务？

Develop engineered T cell therapeutics for cancer treatment.
Focus on autologous T cell therapy.
Target hematologic malignancies and solid tumors.
Advance CER-1236 as their lead development candidate.
Conduct preclinical and clinical research.
Seek strategic partnerships for funding and expertise.
Aim to improve cancer treatment outcomes through immunotherapy.

CERO如何赚钱？

Develop and commercialize engineered T cell therapies.
Generate revenue through licensing agreements and partnerships.
Potentially generate revenue through direct sales of approved therapies.
Focus on research and development to create innovative cancer treatments.

Patients with hematologic malignancies.
Patients with solid tumors.
Hospitals and cancer treatment centers.
Pharmaceutical companies (potential partners).

Proprietary T cell engineering technology.
Intellectual property protection for CER-1236.
Expertise in immunotherapy and cancer biology.
Potential for first-in-class or best-in-class therapy.

什么因素可能推动CERO股价上涨？

Upcoming: Initiation of Phase 1 clinical trial for CER-1236 in hematologic malignancies (2026).
Upcoming: Presentation of preclinical data at a major scientific conference (2026).
Ongoing: Continued research and development efforts to expand the pipeline of T cell therapies.
Ongoing: Pursuit of strategic partnerships and collaborations with pharmaceutical companies.
Ongoing: Efforts to secure additional funding through grants and private placements.

CERO的主要风险是什么？

Potential: Clinical trial failures or delays.
Potential: Regulatory hurdles and delays in obtaining approvals.
Potential: Competition from established immunotherapy companies.
Ongoing: Dependence on a single lead candidate (CER-1236).
Ongoing: Difficulty securing sufficient funding to support research and development.

CERO的核心优势是什么？

Novel T cell therapy approach.
Focus on a significant unmet medical need (cancer).
Experienced leadership in immunotherapy.
Strategic location in a biotechnology hub.

CERO的劣势是什么？

Limited operating history.
Small team and limited resources.
Dependence on a single lead candidate.
High cash burn rate.

CERO有哪些机遇？

Positive clinical trial results for CER-1236.
Strategic partnerships with larger pharmaceutical companies.
Expansion of target indications.
Development of next-generation T cell therapies.

CERO面临哪些威胁？

Competition from established immunotherapy companies.
Regulatory hurdles and delays.
Clinical trial failures.
Difficulty securing funding.

CERO的竞争对手是谁？

Bio-Cure Therapeutics, Inc. — Focuses on cell therapies for cancer. — (BCTXZ)
BioVie Inc. — Develops therapies for neurodegenerative and liver diseases. — (BIVI)
Establishment Labs Holdings Inc. — Medical technology company focused on breast implants. — (ELAB)
Galmed Pharmaceuticals Ltd. — Develops therapies for liver diseases. — (GLMD)
Liminal BioSciences Inc. — Develops therapies for fibrotic and inflammatory diseases. — (LIMN)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Christopher Ehrlich
Headquarters: South San Francisco, US
Employees: 8
Founded: 2021

AI Insight

AI analysis pending for CERO

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CERo Therapeutics Holdings, Inc. do?

CERo Therapeutics Holdings, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Their primary focus is on engineering T cells to target and destroy cancer cells, offering a potential breakthrough in cancer treatment. The company's lead candidate, CER-1236, is an autologous T cell therapy designed to combat both hematologic malignancies and solid tumors. CERo Therapeutics aims to improve patient outcomes by developing more effective and targeted cancer therapies.

What do analysts say about CERO stock?

As of March 16, 2026, there is no available analyst coverage for CERo Therapeutics Holdings, Inc. due to its OTC listing and early stage of development. Key valuation metrics such as price-to-earnings ratio are not meaningful due to the company's negative earnings. Growth considerations center on the successful advancement of CER-1236 through clinical trials and the potential for strategic partnerships. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies.

What are the main risks for CERO?

The main risks for CERo Therapeutics Holdings, Inc. include the inherent uncertainties of clinical development, regulatory hurdles, and competition from established immunotherapy companies. Clinical trial failures or delays could significantly impact the company's value. Securing sufficient funding to support ongoing research and development is also a critical risk. The company's dependence on a single lead candidate (CER-1236) increases its vulnerability to setbacks. Additionally, as an OTC-listed stock, CERO is subject to lower liquidity and higher price volatility.